Skip Nav Destination
Issues
1 March 2002
ISSN 1078-0432
EISSN 1557-3265
Editorial
Minireviews
Minireview
The Biology Behind
Report from the FDA
Regular Articles
Association of High-dose Cyclophosphamide, Cisplatin, and Carmustine Pharmacokinetics with Survival, Toxicity, and Dosing Weight in Patients with Primary Breast Cancer1
William P. Petros; Gloria Broadwater; Donald Berry; Roy B. Jones; James J. Vredenburgh; Colleen J. Gilbert; John P. Gibbs; O. Michael Colvin; William P. Peters
The Association of p21(WAF-1/CIP1) with Progression to Androgen-independent Prostate Cancer1
Karim Fizazi; Luis A. Martinez; Charles R. Sikes; Dennis A. Johnston; L. Clifton Stephens; Timothy J. McDonnell; Christopher J. Logothetis; Jon Trapman; Louis L. Pisters; Nelson G. Ordoñez; Patricia Troncoso; Nora M. Navone
Clinical Trials
Safety and Efficacy of the Multidrug Resistance Inhibitor Incel (Biricodar; VX-710) in Combination with Paclitaxel for Advanced Breast Cancer Refractory to Paclitaxel
Deborah Toppmeyer; Andrew D. Seidman; Michael Pollak; Christy Russell; Katherine Tkaczuk; Shailendra Verma; Beth Overmoyer; Varun Garg; Ene Ette; Matthew W. Harding; George D. Demetri
Phase I Trial of BCL-2 Antisense Oligonucleotide (G3139) Administered by Continuous Intravenous Infusion in Patients with Advanced Cancer1
Michael J. Morris; William P. Tong; Carlos Cordon-Cardo; Marija Drobnjak; William K. Kelly; Susan F. Slovin; Kathryn L. Terry; Karen Siedlecki; Paul Swanson; Mohmed Rafi; Robert S. DiPaola; Neal Rosen; Howard I. Scher
Phase I Trial of the Histone Deacetylase Inhibitor, Depsipeptide (FR901228, NSC 630176), in Patients with Refractory Neoplasms
Victor Sandor; Susan Bakke; Robert W. Robey; Min H. Kang; Mikhail V. Blagosklonny; Jonathon Bender; Rebecca Brooks; Richard L. Piekarz; Eben Tucker; William D. Figg; Kenneth K. Chan; Barry Goldspiel; Antonio Tito Fojo; Stanley P. Balcerzak; Susan E. Bates
Research Articles
Molecular Oncology, Markers, Clinical Correlates
The Predictive Value of bcl-2, bax, bcl-xL, bag-1, fas, and fasL for Chemotherapy Response in Advanced Breast Cancer1
Johanna Sjöström; Carl Blomqvist; Kristina von Boguslawski; Nils-Olof Bengtsson; Ingvil Mjaaland; Per Malmström; Björn Ostenstadt; Erik Wist; Vahur Valvere; Shinichi Takayama; John C. Reed; Eero Saksela
Experimental Therapeutics, Preclinical Pharmacology
Vitamin E Succinate Is a Potent Novel Antineoplastic Agent with High Selectivity and Cooperativity with Tumor Necrosis Factor-related Apoptosis-inducing Ligand (Apo2 Ligand) in Vivo1
Tobias Weber; Min Lu; Ladislav Andera; Harald Lahm; Nina Gellert; Marc W. Fariss; Vladimir Korinek; Wolfgang Sattler; David S. Ucker; Alexei Terman; Andreas Schröder; Wolfgang Erl; Ulf T. Brunk; Robert J. Coffey; Christian Weber; Jiri Neuzil
Local Recurrence in Head and Neck Cancer: Relationship to Radiation Resistance and Signal Transduction1
Anjali K. Gupta; W. Gillies McKenna; Charles N. Weber; Michael D. Feldman; Jeffrey D. Goldsmith; Rosemarie Mick; Mitchell Machtay; David I. Rosenthal; Vincent J. Bakanauskas; George J. Cerniglia; Eric J. Bernhard; Randal S. Weber; Ruth J. Muschel
Exisulind in Combination with Docetaxel Inhibits Growth and Metastasis of Human Lung Cancer and Prolongs Survival in Athymic Nude Rats with Orthotopic Lung Tumors1
Daniel C. Chan; Keith A. Earle; Tom L. M. Zhao; Barbara Helfrich; Chan Zeng; Anna Baron; Clark M. Whitehead; Gary Piazza; Rifat Pamukcu; W. Joseph Thompson; Hector Alila; Peter Nelson; Paul A. Bunn, Jr.
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale within the United States of Bavencio® (avelumab), a pharmaceutical owned by Merck. If any resulting funds are received, they would not be used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.